Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG4010 plus first-line therapy vs placebo in stage IV non-small cell lung cancer
2011-001468-23Phase 2Completed
- Sponsor
- Transgene SA
- Start
- Jun 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing TG4010 + first-line therapy with Placebo + first-line therapy (2 arms). Primary endpoint: Progression-free survival (Phase IIb part). Started Jun 2011; status: completed.
02
Drugs
TG4010
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2011-001468-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001468-23.